ZEN-3694

DB22031InvestigationalSmall molecule

ZEN-3694 is under investigation in clinical trial NCT04840589 (Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors).

Mechanism: Pharmacologically active on Bromodomain-containing protein 4, Bromodomain-containing protein 2, and Bromodomain-containing protein 3
Curator reviewed
Code names: BETi ZEN-3694 · ZEN003694 · ZEN-3694

Resolves to

Compound

UNIIO28XHZ9UQ4

Targets

O60885BRD4P25440BRD2Q15059BRD3Q58F21BRDT

What you can answer from here — as of June 26, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

20Clinical trialsPhase, status and sponsor resolved per trial

11+ReferencesStructured and connected to the statements they support

Which drugs share a target with ZEN-3694, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account